JP2023515270A - Ｔｃｒ／ｂｃｒプロファイリング - Google Patents

Ｔｃｒ／ｂｃｒプロファイリング Download PDF

Info

Publication number
JP2023515270A
JP2023515270A JP2022564450A JP2022564450A JP2023515270A JP 2023515270 A JP2023515270 A JP 2023515270A JP 2022564450 A JP2022564450 A JP 2022564450A JP 2022564450 A JP2022564450 A JP 2022564450A JP 2023515270 A JP2023515270 A JP 2023515270A
Authority
JP
Japan
Prior art keywords
tcr
bcr
layer
probes
sequencing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515270A5 (https=
Inventor
ジェイソン・ペレラ
テイラー・ハーディング
ブリタニー・ミネオ
アリー・エー・カーン
リチャード・ブリドナー
ジェンナ・エル・マリナウスカス
Original Assignee
テンパス・ラボズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンパス・ラボズ・インコーポレイテッド filed Critical テンパス・ラボズ・インコーポレイテッド
Publication of JP2023515270A publication Critical patent/JP2023515270A/ja
Publication of JP2023515270A5 publication Critical patent/JP2023515270A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Amplifiers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022564450A 2020-04-21 2021-04-21 Ｔｃｒ／ｂｃｒプロファイリング Pending JP2023515270A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063013130P 2020-04-21 2020-04-21
US63/013,130 2020-04-21
US202063084459P 2020-09-28 2020-09-28
US63/084,459 2020-09-28
US202163201020P 2021-04-08 2021-04-08
US63/201,020 2021-04-08
PCT/US2021/070440 WO2021217181A1 (en) 2020-04-21 2021-04-21 Tcr/bcr profiling

Publications (2)

Publication Number Publication Date
JP2023515270A true JP2023515270A (ja) 2023-04-12
JP2023515270A5 JP2023515270A5 (https=) 2025-08-15

Family

ID=78270138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564450A Pending JP2023515270A (ja) 2020-04-21 2021-04-21 Ｔｃｒ／ｂｃｒプロファイリング

Country Status (6)

Country Link
US (3) US11414700B2 (https=)
EP (1) EP4139477A4 (https=)
JP (1) JP2023515270A (https=)
AU (1) AU2021259958A1 (https=)
CA (1) CA3174332A1 (https=)
WO (1) WO2021217181A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4271837A4 (en) 2020-12-31 2025-10-15 Tempus Ai Inc SYSTEMS AND METHODS FOR DETECTING MULTIMOLECULAR BIOMARKERS
WO2023064309A1 (en) 2021-10-11 2023-04-20 Tempus Labs, Inc. Methods and systems for detecting alternative splicing in sequencing data
US20250011886A1 (en) * 2021-11-17 2025-01-09 Ampel Biosolutions, Llc Systems and Methods for Targeting COVID-19 Therapies
WO2023115065A2 (en) * 2021-12-17 2023-06-22 Allen Institute Molecular signatures for cell typing and monitoring immune health
EP4499877A4 (en) * 2022-03-25 2026-04-08 Freenome Holdings Inc TCR/BCR Profiling for Cell-Free Nucleic Acid Cancer Detection
BE1031300B1 (fr) 2023-01-30 2024-09-03 Grand Hopital De Charleroi Procede pour l'integration ciblée d'identificateurs moleculaires uniques (ium) et la détection de haute précision d'états médicaux ou cosmetiques
US20240355485A1 (en) 2023-04-13 2024-10-24 Tempus Ai, Inc. Systems and methods for predicting clinical response
CN116751280B (zh) * 2023-05-17 2024-01-26 复旦大学附属中山医院 一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用
EP4550335A1 (en) 2023-10-31 2025-05-07 Tempus AI, Inc. T cell receptor screening methods
WO2025175065A1 (en) * 2024-02-13 2025-08-21 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for assessment of immune response and applications thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020056451A1 (en) * 2018-09-21 2020-03-26 Garvan Institute Of Medical Research Phenotypic and molecular characterisation of single cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635354A (en) 1991-01-09 1997-06-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US9193997B2 (en) * 2010-12-15 2015-11-24 The Board Of Trustees Of The Leland Stanford Junior University Measuring and monitoring of cell clonality
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
EP3227464B1 (en) 2014-12-05 2022-04-20 Foundation Medicine, Inc. Multigene analysis of tumor samples
KR20230006929A (ko) * 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
EP3443149B1 (en) * 2016-04-15 2024-08-14 University Health Network (UHN) Hybrid-capture sequencing for determining immune cell clonality
GB201612242D0 (en) * 2016-07-14 2016-08-31 Genome Res Ltd And Cambridge Entpr Ltd Novel kit
EP3568508A4 (en) * 2017-01-12 2020-12-16 Massachusetts Institute Of Technology METHODS FOR T-LYMPHOCYTE RECEPTOR AND B-LYMPHOCYTE RECEPTOR ANALYSIS
EP3631053A4 (en) * 2017-05-30 2021-05-19 University of Health Network Hybrid-capture sequencing for determining immune cell clonality
WO2018231958A1 (en) * 2017-06-13 2018-12-20 Adaptive Biotechnologies Corp. Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs)
US10957041B2 (en) 2018-05-14 2021-03-23 Tempus Labs, Inc. Determining biomarkers from histopathology slide images
US10801064B2 (en) * 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
AU2019317440B2 (en) 2018-08-06 2026-01-22 Tempus Ai, Inc. A multi-modal approach to predicting immune infiltration based on integrated RNA expression and imaging features
AU2019346427A1 (en) 2018-09-24 2021-05-13 Tempus Ai, Inc. Methods of normalizing and correcting RNA expression data
WO2020081607A1 (en) 2018-10-15 2020-04-23 Tempus Labs, Inc. Microsatellite instability determination system and related methods
US20200258601A1 (en) 2018-10-17 2020-08-13 Tempus Labs Targeted-panel tumor mutational burden calculation systems and methods
US20200365232A1 (en) 2018-10-17 2020-11-19 Tempus Labs Adaptive order fulfillment and tracking methods and systems
EP4198057A1 (en) * 2018-12-05 2023-06-21 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
AU2019418813A1 (en) 2018-12-31 2021-07-22 Tempus Ai, Inc. A method and process for predicting and analyzing patient cohort response, progression, and survival
WO2020142563A1 (en) 2018-12-31 2020-07-09 Tempus Labs, Inc. Transcriptome deconvolution of metastatic tissue samples
US10975445B2 (en) 2019-02-12 2021-04-13 Tempus Labs, Inc. Integrated machine-learning framework to estimate homologous recombination deficiency
EP3924503A4 (en) 2019-02-12 2023-03-08 Tempus Labs, Inc. DETECTION OF LOSS OF HETEROZYGOSIS IN HUMAN LEUKOCYTE ANTIGEN
ES3043308T3 (en) 2019-02-26 2025-11-25 Tempus Ai Inc Systems and methods for using sequencing data for pathogen detection
JP7747524B2 (ja) 2019-05-14 2025-10-01 テンパス エーアイ，インコーポレイテッド マルチラベルがん分類のためのシステムおよび方法
US20200395097A1 (en) 2019-05-30 2020-12-17 Tempus Labs, Inc. Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
EP3977343A4 (en) 2019-05-31 2023-06-14 Tempus Labs CLINICAL TRIAL EVALUATION SYSTEMS AND METHODS
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
WO2021022225A1 (en) 2019-08-01 2021-02-04 Tempus Labs, Inc. Methods and systems for detecting microsatellite instability of a cancer in a liquid biopsy assay
AU2020334901A1 (en) 2019-08-16 2022-03-24 Tempus Ai, Inc. Systems and methods for detecting cellular pathway dysregulation in cancer specimens
US11041200B2 (en) 2019-10-21 2021-06-22 Tempus Labs, Inc. Systems and methods for next generation sequencing uniform probe design
WO2021080978A1 (en) 2019-10-21 2021-04-29 Tempus Labs, Inc. Calculating cell-type rna profiles for diagnosis and treatment
WO2021081253A1 (en) 2019-10-22 2021-04-29 Tempus Labs, Inc. Systems and methods for predicting therapeutic sensitivity
US20210118559A1 (en) 2019-10-22 2021-04-22 Tempus Labs, Inc. Artificial intelligence assisted precision medicine enhancements to standardized laboratory diagnostic testing
US11629385B2 (en) 2019-11-22 2023-04-18 Tempus Labs, Inc. Tumor organoid culture compositions, systems, and methods
WO2021113749A1 (en) 2019-12-04 2021-06-10 Tempus Labs, Inc. Systems and methods for automating rna expression calls in a cancer prediction pipeline
EP4070232A4 (en) 2019-12-05 2024-01-31 Tempus Labs, Inc. SYSTEMS AND METHODS FOR HIGH-THROUGHPUT ACTIVE SCREENING
US20230197269A1 (en) 2020-02-18 2023-06-22 Tempus Labs, Inc. Systems and methods for detecting viral dna from sequencing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020056451A1 (en) * 2018-09-21 2020-03-26 Garvan Institute Of Medical Research Phenotypic and molecular characterisation of single cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAT BIOTECHNOL, vol. 36(1), JPN6025018216, 2018, pages 60 - 10, ISSN: 0005732719 *

Also Published As

Publication number Publication date
US20230121729A1 (en) 2023-04-20
US11414700B2 (en) 2022-08-16
CA3174332A1 (en) 2021-10-28
US20250115954A1 (en) 2025-04-10
WO2021217181A1 (en) 2021-10-28
EP4139477A1 (en) 2023-03-01
US12129519B2 (en) 2024-10-29
AU2021259958A1 (en) 2022-11-17
EP4139477A4 (en) 2024-05-22
US20210355533A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
US12129519B2 (en) TCR/BCR profiling using enrichment with pools of capture probes
JP2023515270A5 (https=)
JP7699261B2 (ja) 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
Kaufmann et al. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis
US12205675B2 (en) Techniques for bias correction in sequence data
Byron et al. Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Liu et al. The methods and advances of adaptive immune receptors repertoire sequencing
KR20220011140A (ko) 종양 분획 평가를 위한 시스템 및 방법
EP2663864B1 (en) Immunodiversity assessment method and its use
JP2024112843A (ja) ゲノム変化を評価するための組成物および方法
CN120193081A (zh) 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US20190390273A1 (en) Hybrid-capture sequencing for determining immune cell clonality
Farmanbar et al. RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia/lymphoma
Barrozo et al. SARS-CoV-2 niches in human placenta revealed by spatial transcriptomics
EP4359569A1 (en) Systems and methods for evaluating tumor fraction
Kiyotani et al. Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy
Li et al. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq
CN105164277A (zh) 用于评估免疫组库的方法
Peng et al. Profiling the TRB and IGH repertoire of patients with H5N6 Avian Influenza Virus Infection by high-throughput sequencing
Galbraith et al. Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections
CN114424291A (zh) 免疫组库健康评估系统和方法
Sun et al. Association of the characteristics of B‑and T‑cell repertoires with papillary thyroid carcinoma
JP2025538871A (ja) 非小細胞肺がん（ＮＳＣＬＣ）患者の薬物応答または死亡もしくはがん進行までの時間を、循環腫瘍ＤＮＡ（ｃｔＤＮＡ）から、ベースラインｃｔＤＮＡレベルおよびｃｔＤＮＡレベルの経時的な縦断的変化の両方からのシグナルを利用して予測する方法
Medina-Herrera et al. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers 2023, 15, 3687
AU2016281193A1 (en) Method of measuring chimerism

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318